Status: Recruiting
Camrelizumab Plus Apatinib and Temozolomide as Neoadjuvant in High Risk Acral Melanoma
Neoadjuvant therapy is feasible in stage Ⅱ-Ⅲ melanoma, Carrelizumab combined with apatinib and temozolomide has synergistic antitumor effects and may improve pathological response.
Participants needed: 60
Trial details
Phase: Phase 2Age: 18-75Biological sex: AllType: InterventionalSponsor: Peking University Cancer Hospital & InstituteUpdated: Mar 3, 2025Locations: 1
Eligibility criteria
age:18-75 years, male or female. [+7]
Patients who have or are currently undergoing additional chemotherapy, radiation... [+7]